JACK KACZMARCZYK: Open Payments
NPI 1427752401 · MUSKEGON, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,609 in 172 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $826 · 2025 $2,609
Food & beverage: $2,602Education: $8
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $415 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $332 |
| Neurocrine BioSciences, Inc. | 22 | $307 |
| Supernus Pharmaceuticals, Inc. | 23 | $245 |
| Otsuka America Pharmaceutical, Inc. | 12 | $224 |
| Axsome Therapeutics, Inc. | 6 | $204 |
| Vanda Pharmaceuticals Inc. | 12 | $194 |
| E.R. Squibb & Sons, L.L.C. | 7 | $167 |
| Teva Pharmaceuticals USA, Inc. | 15 | $154 |
| Alkermes, Inc. | 9 | $147 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, Qelbree, Auvelity, COBENFY, FANAPT, AUSTEDO XR.
Industry payments across MI — which companies pay providers there.
